对工程抗体和蛋白质治疗药物的免疫性风险评估和缓解
Paul J Carter1, Valerie Quarmby2
1Department of Antibody Engineering, Genentech, Inc., South San Francisco, CA, USA. pjc@gene.com.
Nature reviews. Drug discovery
|October 18, 2024
概括
蛋白质疗法为患者提供了显著的益处,但可以引起免疫反应,导致产生影响安全性和有效性的抗药抗体. 本综述探讨了在蛋白质疗法中减轻免疫性风险的挑战和解决方案.
科学领域:
- 生物技术是生物技术.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 蛋白质疗法,包括工程抗体,已经推进了医疗治疗.
- 一个重大挑战是免疫性,患者在这种情况下会产生抗药抗体 (ADA).
- ADA可以不可预测地降低治疗疗效,并危及患者的安全.
研究的目的:
- 审查和确定与抗药抗体相关的关键未解决的挑战.
- 为评估和减轻免疫性风险提出务实的方法.
- 突出在蛋白质治疗开发中需要新解决方案的领域.
主要方法:
- 审查现有文献和临床数据,主要关注抗体疗法.
- 对免疫原性有助于形成的因素的分析.
- 探索临床前评估和缓解策略.
主要成果:
- 尽管取得了进展,但预测和预防免疫性仍然是复杂的.
- 一些免疫性挑战有可处理的解决方案,而另一些需要创新的方法.
- 临床前评估和缓解对于减少临床免疫性事件至关重要.
结论:
- 解决抗药抗体的形成对于优化蛋白质治疗安全性和有效性至关重要.
- 为了克服剩余的免疫性障碍,需要继续研究和开发新的策略.
- 在临床前阶段积极管理免疫性风险对于成功的治疗开发至关重要.
相关概念视频
Immunoprecipitation
5.3K
Immunoprecipitation, or IP, is a widely used technique that employs protein-antibody interactions to isolate proteins or protein complexes in their native state for studying protein-protein interactions, quaternary structures, or supramolecular complexes. Various modifications of the technique, including chromatin IP, cross-linking IP, and fluorescence IP, are commonly used.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation, also known as ChIP, is used to study protein-DNA or...
Chromatin Immunoprecipitation
Chromatin immunoprecipitation, also known as ChIP, is used to study protein-DNA or...
5.3K
Antigens Involved in Adaptive Immunity
463
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
Complete Antigens
Complete antigens possess both immunogenicity and...
463
Cross-reactivity
31.0K
Overview
31.0K


